Chairman of the Board
Before founding MediPharm Labs, Pat enjoyed a 15-year career in the pharmaceutical industry in top sales roles at Sanofi Canada and AstraZeneca Canada, successfully launching a wide range of medical products. He most recently worked at Janssen Pharmaceuticals (Johnson & Johnson) where he led the Hospital Division for Renal and Mental Health products, helping to develop new strategic products and customized drug [bundling] programs for hospitals and specialty patient groups. Pat brought his pharmaceutical perspective to the cannabis industry, with a mission from the outset for MediPharm Labs to standout as a global leader in the pharma-quality manufacture of cannabinoid-based products.
Under Pat’s visionary leadership, MediPharm Labs emerged as a leading specialized contract manufacturing organization (CMO) for Canada’s newly legalized adult-use market, while simultaneously building a multi-jurisdictional, GMP-certified platform to supply the global medical cannabis market. His drive fuelled his chosen team to secure the coveted international pharma-standard GMP licences in short order while also launching a broad range of product formats and production capabilities for medicinal, wellness and adult-use brands.
Pat took MediPharm Labs public on the TSX Venture Exchange in October 2018, shortly thereafter, the OTCQX and FSE exchanges and up-listed to the TSX in July 2019. Pat is a frequent speaker at international cannabis events and conferences. He holds an Honours Bachelor of Science degree in biology from the University of Western Ontario.
Chief Executive Officer, Asia Pacific
Warren brings a wealth of senior leadership to MediPharm Labs Australia, having run both his own small businesses as well as achieved success in the Asia Pacific for a leading international digital marketing agency. Warren completed an Honours Bachelor Computer Science (programming) and was on the leading edge of web development and digital marketing, working first in Canada and the UK before building the Asia Pacific division of a large enterprise marketing agency, MarketOne. Over 8 years, Warren opened four offices, adding 200+ staff in Melbourne, Singapore, Bangalore and Tokyo. He boasts a 15-year history in sales and marketing, consulting to some of the biggest companies in the world.
Mr. Halyk has 35 years of pharmaceutical industry experience including 33 years with Johnson & Johnson. Among his many career highlights, he served as: Vice-President, Sales and Marketing and a member of the Janssen Management Board with responsibility for innovations in direct-to-consumer advertising, patient education and sales force automation; Managing Director of Ortho Biotech, the biopharmaceutical division of Janssen Inc.; and from 2006 until his retirement in 2019 as the President of Janssen Inc. (Canada) where under his leadership, the company became the largest pharmaceutical company in Canada. During his tenure, his accomplishments included, bringing innovative products, services and solutions to market along with new technologies and treatments in oncology, immunology, neuroscience, infectious diseases and vaccines, cardiovascular and metabolism and pulmonary hypertension. Mr. Halyk holds an Honours Business Administration degree from Ivey Business School at Western University. He served as the Chair of the Board of Directors for Rx&D, the industry association for Canada’s Research-Based Pharmaceutical Companies (now named Innovative Medicines Canada) from 2012 until 2013. Before joining Johnson & Johnson, Mr. Halyk worked for pharmaceutical company Warner-Lambert in Toronto.
Shelley is the former President and CEO of Nestlé Canada and a consumer packaged goods industry top executive with an outstanding track record of success. Ms. Martin served in a variety of senior executive roles at Nestlé Canada Inc. from 1990 until she retired after five years as President and Chief Executive Officer in 2018. During her time leading Nestlé Canada, she drove a substantial increase in revenue, market share and profitability and transformed core business units and brands by introducing new formulas, packaging, pricing, global sources of supply and Lean (Six Sigma) tools. In 2018, Nestlé Canada’s annual sales were approximately $2.6 billion. She began her career at General Mills Canada in 1985 and was named one of Canada’s Most Powerful Women by the Women’s Executive Network (WXN) in 2015, 2016 and 2018. Ms. Martin is a member of the Advisory Board of Moosehead Breweries as well as Crosby Molasses, and is a Director of Vineland Research and Innovation Centre, a leader in horticultural research and innovation. From 2016 to 2018, she served as Board Chair of Food & Consumer Products of Canada (FCPC), which represents more than 100 food, beverage, and consumer product manufacturers of all sizes. From 2013 to 2018, she was a Director of The Grocery Foundation, a not-for-profit organization that has raised over $90 million for student nutrition programs. Ms. Martin is a graduate of Wilfrid Laurier University (Bachelor of Business Administration) and earned the Institute of Corporate Directors ICD. D designation in 2016.
Miriam is currently the Director of Pharmacy at Health Sciences North, Northern Ontario’s largest hospital located in Sudbury. She holds a Bachelor of Science in Pharmacy from the University of Toronto and a Master of Science in Pharmacology from Queens University. Her career has encompassed positions as the Executive Director of Community Development at the Northern Ontario School of Medicine, and CEO of the Northeastern Ontario Medical Education Corporation (NOMEC) wherein she worked throughout northern Ontario to facilitate community-based medical clinical education. She also served as Director of Planning and Development of Cambrian College, Executive Director of Cambrian Foundation, and Director of Pharmacy, Director of Rehabilitation Services and Assistant Executive Director of Therapeutic Services at Laurentian Hospital. She was Project Coordinator for the planning and construction of the Glenn Crombie Special Needs Centre, the Northern Centre for Advanced Technology (NORCAT), and the Northeastern Cancer Centre. She is the author and co-author of several health-related papers and studies and is very active in the community both on a personal and professional level. She has been recognized by Northern Ontario Business as a “Woman of Influence”, was the recipient of the Sudbury Business and Professional Women’s Club highest honor – the Bernardine Yackman Award, and has served on the Women’s Health Council of Ontario and Ontario Judicial Appointment Advisory Committee. Raised in northern Ontario, her strongest interest is in projects that address access to health, education, and information technology in northern Ontario.
Marufur serves as an advisor to public companies and private companies planning on going public through direct initial public offerings or reverse mergers. Marufur is one of the leaders of MNP LLP’s Access to Cannabis for Medical Purposes Regulation (ACMPR) team. His principal role has been auditing these companies as well as assisting them in their going public process. He has also helped in securing financing for some of the companies in this sector. Marufur is considered a thought leader in the practical application of the IFRS biological asset standard and measurement of fair value of the assets. He has experience in the medical marijuana sector internationally and has assisted with these companies listing in Canada. Marufur has helped numerous Canadian and international companies go public in Canada. He has worked around the globe, with a special focus on Latin America and Africa and specializes in helping finance these companies in Canada, either through public or private transactions. Marufur has extensive experience working with clients in the technology, mining, pharmaceutical, and gaming sectors. He is also involved with investment funds and Exempt Market Dealers. Marufur is a Chartered Professional Accountant (CPA), qualifying as a Chartered Accountant (CA) in 2001. He currently serves on the PDAC-CPA Canada joint Mining Task Force for IFRS. He also serves as a director to several TSX and TSX-V listed companies.
Interim Chief Executive Officer & Director
Keith Strachan co-founded MediPharm Labs in 2015, utilizing his consultancy expertise in Public Sector RFP and government contracts, compliance for government licensing and local planning, to break the mold and secure the first Health Canada Licence for cannabis oil production without first being a cultivator. A seasoned entrepreneur, Keith has applied his leadership to building out MediPharm Labs’ leading-edge facilities, launching operations and growing its workforce, while also strategically driving business development with the Company’s many supply, contract processing and white label partner LPs.
Dr. Paul Tam, MBBS, FRCP(C), FACP
With more than three decades of clinical research and medical practice experience, Dr. Paul Tam is a globally recognized expert in the field of nephrology and a pioneer in the development of continuous renal replacement therapy for acute kidney injury. In 1996, Dr. Tam founded the Scarborough Regional Nephrology Program where he is currently Medical Director of the largest community nephrology program in Canada. Dr. Tam oversees a team of thirteen nephrologists that provide renal care to over 900 dialysis patients and 4,000 chronic kidney disease patients and is also an active staff nephrologist at The Scarborough Hospital. Dr. Tam is also the Medical Quality Advisor for three major Independent Health Facilities that provide hemodialysis care. Dr. Tam has extensive and highly specialized experience in pharmaceutical development having co-founded and acted as the Medical Director overseeing operations and clinical research for a contract research organization which was ultimately acquired by the Biovail Corporation. Dr. Tam served as a Director of Biovail Corporation after the acquisition and he also served as the Medical Director of Contract Research arm of Biovail Corporation. Dr. Tam continues to be active in clinical research and participate in multi-national trials, product commercialization and is a highly respected subject matter author. Dr. Tam also leads and serves on multiple professional and executive governance committees. He is an active member and past Section Chair representing the Nephrology Specialty of the Ontario Medical Association, and active member and past Chair of the Ontario Association of Nephrologists. In the past he has also served on the Boards of Directors for pharmaceutical companies. Dr. Tam received his medical degree from The University of Hong Kong and completed further specialization at the University of Toronto, Canada.
Chris Taves was appointed Chief Operating Officer, BMO Capital Markets in January 2018. In this role, he has oversight of all balance sheet and risk taking activity, as well as regulatory, compliance, and operational functions to ensure they are optimized to satisfy client needs and BMO FG requirements.
Mr. Taves brings over 20 years of customer facing experience covering corporate and institutional clients across a wide range of products, including derivatives, investments, and corporate finance, working closely with I&CB and all areas within Trading Products. Since joining BMO in 2009, he has taken on broader mandates within the Trading Products team, most recently as Co-Head of Global Trading Products.
Mr. Taves is part of the BMO Capital Markets Operating and Executive Committees, the board of BMO Capital Market’s US broker-dealer – BMO Capital Markets Corp., the board of BMO China, and various other leadership committees within BMO Capital Markets and BMO Financial Group.
Mr. Taves holds an MBA from the Ivey School of Business at the University of Western Ontario, a Mathematics degree from the University of Waterloo, and is a Chartered Professional Accountant. He is a member of the United Way Toronto and York Region Major Individual Giving Cabinet and a Director on the board of Armagh, a second-stage housing program for abused women, Operating and Executive committees.